Clinical utility of 0.025-inch guidewire VisiGlide2TM in the endoscopic retrograde cholangiopancreatography-related procedures

Table 4 Procedure conducted after insertion into the bile duct and pancreatic duct

	VisiGlide2TM		VisiGlideTM
Procedure conducted	n	Success rate of procedure	n	Success rate of procedure	P value
ENBD	60	98.3 (59/60)%	51	100 (51/51)%	NS
ENPD	5	100 (5/5)%	3	100 (3/3)%	NS
ENGBD	5	80.0 (4/5)%	1	100 (1/1)%	NS
EGBS	2	100 (2/2)%	1	0 (0/1)%	NS
EBS	95	100 (95/95)%	78	100 (78/78)%	NS
EPS	30	100 (30/30)%	22	100 (22/22)%	NS
EML	2	100 (2/2)%	2	100 (2/2)%	NS
Placement of MS	12	100 (12/12)%	8	100 (8/8)%	NS
Lithotomy	88	100 (88/88)%	69	100 (69/69)%	NS
Bile duct biopsy	8	100 (8/8)%	9	100 (9/9)%	NS
Pancreatic duct biopsy	0	-	1	100 (1/1)%	NS
Peroral cholangioscopy	2	100 (2/2)%	1	100 (1/1)%	NS
IDUS	10	100 (10/10)%	6	100 (6/6)%	NS
Bile duct brushing cytology	12	100 (12/12)%	9	100 (9/9)%	NS
Pancreatic duct brushing cytology	2	100 (2/2)%	2	100 (2/2)%	NS
		Total 333 99.4 (331/333)		Total 263 99.6 (262/263)%	NS
Guidewire type straight angle	127		34		NS
	75		0		NS

ENBD: Endoscopic nasobiliary drainage; ENPD: Endoscopic nasopancreatic drainage; ENGBD: Endoscopic nasogallbladder drainage; EGBS: Endoscopic gallbladder stenting; EBS: Endoscopic biliary stenting; EPS: Endoscopic pancreatic stenting; EML: Endoscopic mechanical lithotripsy; MS: Metallic stent; IDUS: Intraductal ultrasonography; NS: Not significant.